Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neumora Therapeutics (NMRA) Cash from Operations (2022 - 2026)

Neumora Therapeutics' quarterly Cash from Operations came in at 46404000.0 in Q1 2026, up 21.94% year-on-year from 38054198.97 in Q1 2025, and up 3.23% quarter-over-quarter from 47955000.0 in Q4 2025.

Neumora Therapeutics has reported Cash from Operations for 5 years, with the latest figure at 46404000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Cash from Operations rose 21.94% year-over-year to 46404000.0; the trailing twelve-month figure through Mar 2026 stood at 193396000.0 (up 3.03% YoY), and the FY2025 full-year result was 206440000.0, down 12.85% from the prior year.
  • Cash from Operations for Q1 2026 stood at 46404000.0, up from 47955000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 30366000.0 in Q4 2022, with the low at 59448000.0 in Q1 2025.
  • Average Cash from Operations over 5 years is 44958857.14, with a median of 47203000.0 recorded in 2023.
  • Peak annual rise in Cash from Operations reached 29.91% in 2024, while the deepest fall reached 81.03% in 2024.
  • Tracing NMRA's Cash from Operations over 5 years: stood at 30366000.0 in 2022, then slumped by 69.41% to 51442000.0 in 2023, then gained by 2.14% to 50340000.0 in 2024, then climbed by 4.74% to 47955000.0 in 2025, then rose by 3.23% to 46404000.0 in 2026.
  • The last three Cash from Operations figures came in at 46404000.0 (Q1 2026), 47955000.0 (Q4 2025), and 46633000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Operations (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -1.67 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -12.20 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -2.49 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 1.43 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 1.08 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 70.50 Mn
10 Neumora Therapeutics 328.27 Mn 328.27 Mn - -46.40 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -46.40 Mn
Mar 31, 2026 -46.40 Mn
Dec 31, 2025 -47.96 Mn
Dec 31, 2025 -47.96 Mn
Sep 30, 2025 -46.63 Mn
Sep 30, 2025 -46.63 Mn
Jun 30, 2025 -52.40 Mn
Jun 30, 2025 -52.40 Mn
Mar 31, 2025 -59.45 Mn
Mar 31, 2025 -59.45 Mn
Dec 31, 2024 -50.34 Mn
Dec 31, 2024 -50.34 Mn
Sep 30, 2024 -33.48 Mn
Sep 30, 2024 -33.48 Mn
Jun 30, 2024 -56.16 Mn
Jun 30, 2024 -56.16 Mn
Mar 31, 2024 -42.96 Mn
Mar 31, 2024 -42.96 Mn
Dec 31, 2023 -51.44 Mn
Dec 31, 2023 -51.44 Mn
Sep 30, 2023 -47.77 Mn
Sep 30, 2023 -47.77 Mn
Jun 30, 2023 -31.02 Mn
Jun 30, 2023 -31.02 Mn
Mar 31, 2023 -33.04 Mn
Mar 31, 2023 -33.04 Mn
Dec 31, 2022 -30.37 Mn
Dec 31, 2022 -30.37 Mn